Institute of HIV Research and Innovation
Bangkok, 10330, Thailand
Location status: Recruiting
Location contact
Nitiya Chomchey, RN, PhD
CONTACT
Somchai Sriplienchan, MD, MPH
PRINCIPAL_INVESTIGATOR
Tassanee Luekasemsuk, MSc
CONTACT
NCT Number: NCT00796263
The purpose for this protocol is to provide safe and effective standard ART to SEARCH 010 and SEARCH 013 participants. Participants are enrolled in an acute HIV infection study (SEARCH 010 protocol: 'Establish and characterize an acute HIV infection cohort in a Thai high-risk population') or in a study of chronic HIV infection (SEARCH 013 protocol 'Characteristics of immunity in gut mucosa, spinal fluid, lymph node and blood of HIV negative and HIV positive Thais').
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 3
Bangkok, 10330, Thailand
Location status: Recruiting
Nitiya Chomchey, RN, PhD
CONTACT
Somchai Sriplienchan, MD, MPH
PRINCIPAL_INVESTIGATOR
Tassanee Luekasemsuk, MSc
CONTACT
To compare systemic and tissue compartments (genital secretion, CNS, gut and lymph node) outcomes among individuals who initiate HIV treatment during acute vs. chronic HIV infection. The outcomes will be compared by stages of infection and antiretroviral regimens. Participants are enrolled in an acute HIV infection study (SEARCH 010 protocol: 'Establish and characterize an acute HIV infection cohort in a Thai high-risk population') or in a study of chronic HIV infection (SEARCH 013 protocol 'Characteristics of immunity in gut mucosa, spinal fluid, lymph node and blood of HIV negative and HIV positive Thais') with the latter serving as controls for the acutely infected individuals.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 (lamivudine) or 2 (lamivudine + abacavir) nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications once daily
plus
dolutegravir(DTG) 50 mg orally once daily
Other names: Triumeq, Dovato
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
Time frame: 10 years
The NPZ-4 score, a composite score of neuropsychological testing ranges from -2.2 to 2.1, with a mean of 0. The score is used to assess cognitive function in studies involving HIV and antiretroviral therapy. A higher score indicates better cognitive performance.
Time frame: 10 years
Time frame: 10 years
The impact of syphilis and COVID-19 on CD4 count, CD4/CD8 ratio and HIV VL will be assessed during co-infection and after resolution. Given the duration of cohort follow-up, additional or new infections may be assessed for impact as incidence in the cohort increases.
Contact information is provided by the study sponsor or research team.
Nitiya Chomchey, RN, PhD
CONTACT
Tassanee Luekasemsuk, MSc
CONTACT
SEARCH Research Foundation
Other
Acronym: AAHIV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00796146
Acute HIV Infection
Bangkok, Thailand
View Trial DetailsNCT05719441
Acute HIV Infection
Birmingham, Alabama, United States
View Trial DetailsNCT06484335
ART, Acute HIV Infection
Pathum Wan, Bangkok, Thailand
View Trial DetailsNCT05728996
Acute HIV Infection
Amsterdam, North Holland, Netherlands
View Trial Details